^
Association details:
| Biomarker: | RAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) + Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
Excerpt:
Eligibility included patients with KRAS WT mCRC (later amended to include only RAS WT mCRC)...The objective response rate (ORR) was 16%. Median progression free survival (PFS) was 3.7 months (90% confidence interval [CI], 2.3-7.1). Median overall survival (OS) was 12.1 months (90% CI, 7.5-14.3)....The combination of cabozantinib and panitumumab has activity.
DOI:
10.1002/onco.13678
